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Abstract
Background: Synuclein gamma (SNCG) expression is associated with advanced disease and chemoresistance in
multiple solid tumors. Our goal was to determine if SNCG protein expression in ovarian cancer was correlated with
clinicopathologic variables and patient outcomes.
Methods: Tissue microarrays from primary tumors of 357 ovarian, fallopian tube, and primary peritoneal cancer patients,
who underwent primary surgery at Roswell Park Cancer Institute between 1995 and 2007, were immunohistochemically
stained for SNCG. A pathologist blinded to patient data scored tumors as positive if ≥10 % of the sample stained for
SNCG. Medical records were reviewed for clinicopathologic and demographic variables. Between the positive and
negative groups, Wilcoxon rank-sum test was used to compare the median ages and Fisher’s exact test was used to
compare groups in categorical variables. Cox proportional hazard models examined associations between SNCG and
overall and progression-free survival.
Results: The median follow-up was 36 months, median overall survival was 39 months, and median progression-free
survival was 18 months. SNCG presence was associated with clinical variables of serous histology, grade 3 disease,
suboptimal debulking, ascites at surgery, FIGO stage III-IV cancer, or initial CA-125 level >485. There was no significant
difference in overall survival (HR 1.06 95 % CI 0.81–1.39 P 0.69) or progression-free survival (HR 1.16 95 % CI 0.89–1.50
P 0.28) for patients with or without SNCG expression.
Conclusions: SNCG expression in ovarian cancer is frequent in patients with high-risk features, but it does not correlate
with chemotherapy response, overall survival, or progression-free survival.
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Background
Ovarian cancer is a leading cause of cancer mortality in
women, accounting for more deaths than any other
gynecologic malignancy in the United States [1]. While
overall cancer incidence and mortality rates for gynecologic
malignancies have declined in the past decade, progress in
ovarian cancer outcomes has been slow. Despite develop-
ments in cytotoxic chemotherapy, five-year survival rates
for women diagnosed with ovarian cancer remain less than
50 % [2].
High rates of recurrence and associated mortality,
coupled with advancements in the characterization of
intracellular signaling pathways in carcinogenesis, have
prompted investigation into other potential targets that
can be used in the treatment of ovarian cancer, such as
intracellular signaling pathways [3]. Among such targets,
synuclein gamma (SNCG) was proposed as a potential
target in ovarian cancer therapy [4].
Synucleins are a family of neuronal proteins expressed
primarily in the peripheral nervous system. To date, three
synuclein proteins have been identified: synuclein- α
(SNCA), synuclein- β (SNCB), synuclein- γ (SNCG) [5, 6].
The former two, SNCA and SNCB, have been implicated
in neurodegenerative disorders, such as Parkinson’s and
Alzheimer’s disease [7, 8], while SNCG has been primarily
linked with cancer. SNCG was first discovered in breast
cancer tissue [9] and has since been detected in multiple
solid tumors, including breast, lung, liver, esophagus,
colon, bladder, pancreatic, and prostate cancers [10].
SNCG has also been identified in gynecologic processes,
including benign pathology (endometriosis), as well as
endometrial and ovarian cancers [10, 11]. SNCG expres-
sion occurs with advanced disease and chemoresistance in
many cancers, and in breast cancer, SNCG has been
causatively linked to increased proliferation, metastasis,
and drug resistance [12].
Recent studies have demonstrated the role of synucleins
as potential biomarkers in several cancer types, including
ovarian cancer [13]. Several studies by immunohistochem-
istry (IHC) analysis demonstrated high levels of SNCG
expression in up to 73 % of epithelial ovarian cancers [14–
16] and one study showed that SNCG overexpression may
promote the metastatic potential of ovarian cancer cells
[17]. These findings suggest that SNCG may be a potential
prognostic marker as well as a target for therapeutic drug
development. Studies examining the correlation of SNCG
expression with clinical outcomes are lacking, however, lim-
ited only to a single meta-analysis of gene expression pro-
files in ovarian cancer [18].
In this study, SNCG expression levels were examined
using immunohistochemistry in primary and metastatic
tumors of 357 patients with ovarian, fallopian tube, and
primary peritoneal cancer. In particular, we examined
the association of SNCG expression in ovarian cancer
with worse outcomes, such as decreased progression




After obtaining IRB approval, the Pathology archive at
Roswell Park Cancer Institute, Buffalo, New York was
searched for ovarian, fallopian tube, and primary peritoneal
cancer cases from 1995 to 2007. A chart review was
conducted with extraction of clinical information, including
patient’s age at the time of diagnosis, the surgical stage,
postoperative treatment. All patients underwent a primary
surgical staging surgery, including total abdominal
hysterectomy with bilateral salpingo-oophorectomy, with or
without pelvic and para-aortic lymph nodes dissection and
pelvic washings, depending on tumor stage. Patients were
treated according to National Comprehensive Cancer Net-
work guidelines (https://www.nccn.org). Patient’s general
information and tumor features are summarized in Table 1.
Histologic evaluation and high-density tissue microarray
(TMA) preparation
Tumor grade was assessed using the International
Federation of Gynecology and Obstetrics (FIGO) system
and tumor stage was assigned based on the 2014 FIGO
surgical staging guidelines. All slides were examined by a
gynecologic pathologist for confirmation of tumor
morphology and tumor grade. The viable tumor tissues and
control tissues (fallopian tube) from each case were circled
by pathologists. 0.6 mm tissue cores were punched and
arrayed into high-density TMA receipting blocks.
Immunohistochemistry
Tissues were prepared for analysis, as previously described
by Mhawech-Fauceglia et al. [19]. Briefly, high-density
TMA blocks were sectioned in 4 μm thickness followed
by deparaffinization with xylene, then washed with etha-
nol. Sections were cooled for 20 min and incubated for
10 min with 3 % H2O2 to quench endogenous peroxidase
activity. Blocking was performed using serum-free protein
block, Dakocytomation (Carpenteria, CA) for 30 min.
Antigen retrieval was done using a citrate-based buffer
(pH 6; Bond Epitope Retrieval Solution, Leica Biosystems)
and sections were incubated with the SNCG antibody
(Abcam) for 1 h at room temperature on the Dako Auto-
stainer Plus. The diaminobenzidine complex was used as
a chromogen. Immunostained slides were blindly reviewed
and scored by two gynecologic pathologists. Immunostain
for SNCG was present in both the nucleus and cytoplasm.
Immunoreactivity was semiquantitatively scored in immu-
nointensity of 0 (negative), 1 + (weak), 2+ (moderate) and
3+ (strong) and immunopercentage of <10 %, 10–50 %
and >50 %. For the sake of statistical analysis, tumors were
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grouped as positive (SNCG+) or negative (SNCG-).
Tumors were considered SNCG+ if ≥10 % of the tumor
epithelial cells were immunoreactive with immunointensity
of ≥2. Examples of positive and negative cases are
illustrated in Fig. 1a-d.
Real time PCR
RNA from benign fallopian tube epithelium and ovarian
cancer tissues was reverse transcribed. First-strand cDNA
synthesis was performed using 700 ng of RNA and M-MLV
reverse transcriptase (Life Technologies). Real time PCR
was performed using Taqman reagent in a QuantStudio 5
system and primers to SNCG and the housekeeping gene
TBP (Applied Biosystems/Life Technologies). Fold-change
values were calculated using TBP as the housekeeping
gene.
Statistical analyses
To test the association between the biomarker and the
clinical parameters, Wilcoxon rank-sum test was used to
compare the median ages and Fisher’s exact test was used
to compare frequencies and percentages for categorical
variables. Progression-free survival (PFS), was defined as
observed length of time from date of diagnosis to recur-
rence or censoring at date of last contact. Overall survival
(OS) was defined as observed length of life from date of
diagnosis to death or censoring at date of last contact. For
survival analysis, Kaplan-Meier curves were used to
estimate PFS, and OS curves. Curves were compared for
tumors with and without SNCG expression using the log-
rank test. Univariate cox proportional hazards models were
used to estimate hazard ratios for SNCG status for both the
OS and PFS outcomes. Multivariate Cox regression was
then conducted with SNCG expression as the main
predictor and adjustment for clinical factors that were
associated with SNCG expression (CA125 level, ascites,
debulking status, FIGO grade, tumor stage and histologic
subtype). Since several of the clinical covariates were highly
associated with each other, sensitivity of the hazard ratio es-
timates for SNCG was examined after adjustment for each
clinical variable in separate models. All reported p values
are two sided with P < 0.05 significance. Statistical analyses
Table 1 Clinical and Pathologic Features of Patients
Variable N (%)
No. of patients 357







≤ 485 141 (53.2)












Primary Site of Disease
Ovarian 300 (84.5)
Primary Peritoneal 53 (14.9)
Fallopian Tube 2 (0.6)
Histologic subtype
Serous 262 (73.6)















Alive, No evidence of disease (ANED) 67 (18.8)
Alive, with evidence of disease (AWED) 22 (6.2)
Table 1 Clinical and Pathologic Features of Patients (Continued)
Died of Disease (DOD) 268 (75.0)
Survival Time (months)
Median 39
95 % CI 34–44
Progression-free survival (months)
Median 18
95 % CI 15–23
Some clinical information were missing from cases and thus the sum of cases
for each feature listed may not equate to 357
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was performed using SAS v 9.4. Unpaired t-test was used
to compare SNCG mRNA levels in benign fallopian tube
and ovarian cancer tissues using Graphpad Prism version
6.0 (Graphpad Software, La Jolla, CA, USA).
Results
Patient characteristics
The clinical and pathologic features of 357 patients with
primary ovarian, fallopian tube, and primary peritoneal
cancer are summarized in Table 1. The mean age at
diagnosis was 63 years. All patients (n = 357) underwent
primary surgery with 82.5 % optimal debulking. No
patients received neoadjuvant chemotherapy or radiation
therapy. The majority of patients had advanced stage
(FIGO Stage III/IV: 81.1 %), were serous type (73.6 %)
and high-grade (FIGO Grade 3: 91.3 %) disease. About
70 % of patients had preoperative ascites and 46.8 % had
CA-125 levels > 485 U/mL at the time of surgery.
Median follow-up time was 36 months (range 0–179
months). At the time of data analysis, 67.2 % of patients
had experienced disease recurrence and 24.9 % were
surviving.
Clinical characteristics and SNCG expression
SNCG expression was positive in 72 % (257/357) of
primary tumors. Examples of positive and negative cases
are illustrated in Fig. 1a-d. SNCG was expressed in
different types of ovarian cancers as well, including
fallopian tube, endometrioid carcinoma, clear cell
carcinoma, and low grade serous carcinoma (Fig. 2).
SNCG overexpression was associated with tumor type,
stage, grade and other clinical parameters (Table 2).
SNCG overexpression was significantly higher in cases
with serous histology than in other histologic variants
(p < 0.0001). In 212 cases with serous histology, 85 % of
cases were SNCG positive while only 43 % of other types
were SNCG positive. Similarly, SNCG overexpression
was much more common in high grade tumors (73 %)
than in low grade (47 %) (p = 0.01). Stage III/IV disease
had significantly high SNCG expression in comparison
to stage I/II (p < 0.0001). About 88 % of suboptimal
debulking tumors showed SNCG overexpression in com-
parison to 69 % of optimal debulking cases (p = 0.004).
Patients with ascites also showed significantly higher
SNCG expression than those without ascites (p = 0.01).
When dividing CA-125 scores of below and above 485,
SNCG expression was marginally associated with high
CA-125 expression as well (p = 0.02). There was no
association between age at diagnosis or site of primary
disease and SNCG expression.
To provide a quantitative measure of SNCG levels
using real time PCR, RNA from tissue samples outside
of the cases used for the tissue microarray, was analyzed.
SNCG expression from benign human fallopian tube
epithelium and ovarian cancer tissues was compared.
Benign fallopian tube epithelium expressed less SNCG
A B
C D
Fig. 1 Immunohistochemical staining of SNCG in ovarian tumor sections in the TMA. Representative sections of negative b and positive d SNCG
expression with corresponding H&E staining a, c are shown. Brown color (arrow) represents positive staining for SNCG
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than ovarian cancer tissues (Additional file 1: Figure S1),
which supports the immunohistochemical analysis of
SNCG (Fig. 2).
Survival analyses
The median OS for the entire study group was 39 months
(95 % CI: 34–44 months) and 5-years OS was 31.57 %.
Median progression-free survival (PFS) was 18 months
(95 % CI: 15–23). There was no significant difference in OS
(HR 1.06; 95 % CI 0.81–1.39, p = 0.69) or PFS (HR 1.16;
95 % CI 0.89–1.50, p = 0.28) for patients with SNCG+
compared to those with SNCG- tumors (Fig. 3). The lack
of association between SNCG expression and OS and PFS
persisted after adjustment for all clinical variables asso-
ciated with SNCG (Additional file 2: Table S1).
Metastatic disease
We further explored SNCG expression in metastases.
Among patients with metastatic tumor samples (n = 184),
153 (83 %) of metastatic tumors demonstrated SNCG ex-
pression. The presence of SNCG expression was compared
between primary and metastatic tumors within the same
patient: 12 (6.6 %) metastatic tumors gained expression of
SNCG, 34 (18.6 %) lost expression, 119 (64 %) maintained
expression, and 19 (10.4 %) never demonstrated SNCG ex-
pression (Table 3). The 5-years OS by groups were: 41.67 %
for tumors gained expression of SNCG, 32.09 % for lost ex-
pression, 20.59 % for maintained expression, and 21.05 %
Fig. 2 Immunohistochemical staining of SNCG in different ovarian
tumor types in the TMA. Representative sections of H&E that are SNCG
positive are shown FT: fallopian tube, EMC: endometrioid carcinoma,
CCC: clear cell carcinoma, LG-SC: low grade serous carcinoma. Brown
color represents positive staining for SNCG. Each core is 1 mm
in diameter
Table 2 Clinical Factors by SNCG expression status
SNCG positive SNCG negative p-value
No. of patients (n = 357) 257 (72 %) 100 (28 %)
Age, year
Median 63.0 63.5 0.93
Range 22–91 36–93
CA125 level
≤ 485 93 (48.7 %) 48 (64.9 %) 0.02
> 485 98 (51.3 %) 26 (35.1 %)
Ascites
No 44 (24.4 %) 29 (40.8 %) 0.01
Present 136 (75.6 %) 42 (59.2 %)
Debulking Status
Optimal 169 (78.6 %) 76 (92.7 %) 0.004
Suboptimal 46 (21.4 %) 6 (7.3 %)
Stage
I/II 30 (12.2 %) 34 (36.6 %) <0.0001
III/IV 215 (87.8 %) 59 (63.4 %)
Primary Site of Disease
Ovarian 219 (85.9 %) 81 (81.0 %) 0.28
Primary Peritoneal 34 (13.3 %) 19 (19.0 %)
Fallopian Tube 2 (0.8 %) 0 (0.0 %)
Histologic subtype
Serous 181 (82.7 %) 31 (38.3 %) <0.0001
Non-serous 38 (17.3 %) 50 (61.7 %)
Grade (FIGO)
1/2 11 (5.8 %) 12 (16.0 %) 0.01
3 177 (94.2 %) 63 (84.0 %)
Recurrence
No 23 (19.49 %) 15 (29.41 %) 0.17
Yes 95 (80.51 %) 36 (70.59 %)
Status
Alive 60 (23.3 %) 29 (29.0 %) 0.28
Dead 197 (76.7 %) 71 (71.0 %)
Percentages are based on denominators of available data due to missing
information from cases
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never demonstrated SNCG expression. There was no
significant difference in OS among patients in whom
primary tumors gained SNCG expression, lost SNCG
expression, maintained SNCG expression, or never
expressed SNCG (log-rank p = 0.23).
SNCG expression and chemotherapy response/platinum
resistance
We further explored the impact of SNCG on chemo-
therapy response. Table 4 demonstrates the distribution
of SNCG expression by platinum-refractory (defined as
disease progression with first-line chemotherapy) or
platinum-sensitive (defined as disease recurrence within
6 months of first-line chemotherapy) disease status
compared to those patients with no evidence of disease
(NED). Results show a marginally greater prevalence of
platinum-refractory cases in cases with positive SNCG
expression (p = 0.08). There was no significant difference
in SNCG status in patients with platinum-sensitive
disease (p = 0.79).
Discussion
This study is the first to formally evaluate the proposed
association between SNCG protein expression and clinical
outcomes in patients with ovarian, fallopian tube, and
primary peritoneal cancers. SNCG is a new potential
biomarker and demonstrates to be specific and reliable for
immunohistochemistry in formalin-fixed and paraffin-
embedded tissue sections. SNCG has been examined in
several different tumor types [10, 13–16]. Although the
cut-off value of immunoreactivity for positive and negative
SNCG has not been established for each tumor type, we
found it was meaningful and reproducible in ovarian
cancer when 10 % of tumor cells have moderate to strong
immunoreactivity for SNCG. In our series of 357 patients,
expression of SNCG was identified in 72 % of primary
tumors, a percentage similar to the 73 % expression that
has previously been reported in ovarian carcinomas [14].
The hypothesis, namely that SNCG expression was associ-
ated with worse clinical outcomes, was refuted, as the
results of our study found no association between SNCG
expression and OS or PFS in primary tumors.
While SNCG expression did not correlate with clinical
outcomes such as PFS, OS, or chemoresistance, the
results of our study did find that there was a significant
association between SNCG expression and high-risk
clinicopathological factors, such as serous histology, high
grade disease, advanced stage, and suboptimal debulking
surgery. These associations suggest that while SNCG
expression might not be a single prognostic marker, it
A B
p=0.69 p=0.27
Fig. 3 Kaplan–Meier survival curves for patients with ovarian cancer stratified according to SNCG expression (positive versus negative). Curves for
a overall survival and b progression-free survival are shown
Table 3 SNCG Expression in Metastases of Primary Tumors
Primary/Metastasis N N event Median OS (months) 2 years OS 5 years OS
−/+ (Gained expression) 12 10 47 (30,102) 91.67 % 41.67 %
+/− (Lost expression) 34 26 32 (17,55) 58.82 % 32.09 %
+/+ (Maintained expression) 118 104 39 (27,44) 65.25 % 20.59 %
−/− (Never expressed) 19 17 17 (9,44) 47.37 % 21.05 %
Log-rank p = 0.23
Combined Metastatic Expression
Positive 130 114 40 (29,44) 67.69 % 22.65 %
Negative 53 43 29 (15,44) 54.72 % 28.18 %
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may be an indicator for high-risk disease and may play a
role in the pathogenesis of disease progression. Further-
more, SNCG expression may provide additional evidence
of disease burden, given its association with advanced
high-grade disease. Given its potential as a marker for
high-risk disease, future studies should focus on the
potential role of secretory SNCG a surrogate marker for
disease burden, such as CA125. Prior studies have
demonstrated that SNCG is detectable in the serum of
patients with cancer [20–23]. The next direction would
be to test serum samples from patients that were
collected at the same time as tumor tissue in order to
correlate serum and tissue SNCG levels.
In regards to SNCG expression in metastatic ovarian
cancer, our data did not demonstrate a significant differ-
ence in OS among patients in whom primary tumors
gained or lost SNCG expression; however, our data did
demonstrate that the majority of metastatic tumors
(83 %) demonstrated SNCG expression. This data sup-
ports prior studies that implicate SNCG overexpression
may promote the metastatic potential of ovarian cancer
cells [17] and further supports the association of SNCG
expression with high-risk clinicopathologic disease. Our
findings of high levels of SNCG expression in ovarian
cancer were consistent with SNCG expression in
multiple cancer types, including breast, liver, prostate,
and colon cancer [14, 21, 24, 25]. However, unlike breast
[12] and endometrial cancers [19] in which high SNCG
expression has been correlated with adverse clinical
outcomes, our study found no correlation between high
SNCG expression and clinical outcomes.
There are several possibilities for the lack of associ-
ation with OS or PFS in this study in ovarian cancer.
First, the study may have been underpowered to detect a
significant difference in clinical outcomes. The associ-
ation of SNCG expression with high-risk disease would
suggest that there is a difference in clinical outcomes
such as PFS or OS, however this was not seen in our
cohort. Next, ovarian cancer is a heterogeneous cancer
with multiple histologic subtypes and underlying
molecular aberrations [26] and thus SNCG expression
may influence tumor phenotype differently depending
on co-existing histologic and molecular factors. Further-
more, as SNCG expression is not specific to ovarian
cancer, its function in ovarian cancer may be a feature of
malignancy in general. Finally, we evaluated the presence
of SNCG, not its function, nor its level of expression.
Tumors may change such genomic outcomes and our
study is insufficient to determine either the underlying
somatic or germline polymorphisms or the epigenetic
actions on SNCG genes. Future studies might focus on
the correlation of SNCG protein and gene expression in
combination with other markers of disease, such as
CA125 levels.
In conclusion, this study found that while SNCG
expression is often present in ovarian carcinoma, the
positive or negative expression of SNCG protein alone is
not independently associated with clinical prognosis. Our
results did indicate that SNCG expression is associated with
clinicopathologic features of high-risk disease, suggesting
that SNCG expression may play a role in severity of disease
and be a marker for aggressive disease. Furthermore, as
targeted drug therapy develops, recognition of SNGC
expression in ovarian cancer will remain important as we
continue to discover ways to improve outcomes in patients
diagnosed with this deadly disease.
Conclusions
Expression of SNCG is associated with clinicopathologic
variables of aggressive and advanced disease but not with
overall survival or progression free survival. SNCG may
serve as a novel biomarker for aggressive or advanced
ovarian carcinoma and warrants further investigation to
determine its role in this disease.
Additional files
Additional file 1: Figure S1. Expression of SNCG mRNA in benign
fallopian tube epithelium and ovarian cancer tissues. RNA from human
benign fallopian tube epithelium and ovarian cancer tissues was subjected
to RT-real time PCR for SNCG. SNCG as a ratio of the housekeeping gene
TBP is presented using delta delta CT calculations. * = p < 0.05. FT – fallopian
tube; OvCa – ovarian cancer. (PPTX 64 kb)
Additional file 2: Table S1. Hazard ratios (HR) from multivariate Cox
regression models for PFS and OS involving SNCG expression and
adjusting for relevant demographic and clinical factors. (DOCX 123 kb)
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CA-125: Cancer antigen-125; FIGO: International Federation of Gynecology
and Obstetrics; HR: Hazard ratio; NED: No evidence of disease; OS: Overall
survival; PFS: Progression-free survival; SNCA: Synuclein-alpha;
SNCB: Synuclein-beta; SNCG: Synuclein gamma; TMA: Tissue microarray; U/
mL: Units per milliliter; Yr: Year
Table 4 SNCG expression in response to chemotherapy.
Comparisons between patients with platinum-refractory (defined
as disease progression with first-line chemotherapy) and patients
with no evidence of disease (NED) or platinum-sensitive disease
status (defined as disease recurrence within 6 months of first-line






No 20 (18.7 %) 46 (28.0 %) 0.08
Yes 87 (81.3 %) 118 (72.0 %)




No 40 (27.6 %) 6 (31.6 %) 0.79
Yes 105 (72.4 %) 13 (68.4 %)
Strohl et al. Journal of Ovarian Research  (2016) 9:75 Page 7 of 8
Acknowledgements
We would like to acknowledge the Pathology Core Facility at Northwestern
University for assistance with tissue microarray and immunohistochemistry
staining. We also are grateful to Ms. Zhenxiao Lu from the Kim lab for
technical assistance.
Funding
This work was funded by the Rivkin Ovarian Cancer Fund (JJW).
Availability of data and materials
The datasets supporting the conclusions of this article are included within
the article.
Authors’ contributions
AS, KM, JJK, BB, JJW, JCS were involved in the conception and design of the
study. JJW, BB, WB, PJF, KO, CM, SA were involved in the acquisition of cases
and tissue microarray construction. AS, KM, JJK, JJW, IBH, DMS analyzed and
interpreted the data. AS, KM, JJK, BB, JJW, JCS, WB, PJF, KO, CM, SA, IBH, DMS
were involved in the writing, review and revision of manuscript. Study was
supervised by JJK and JJW. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
This study was approved by the Institutional Review Board at Roswell Park
Cancer Institute in accordance with U.S. Department of Health Regulations.
Author details
1Division of Gynecologic Oncology, Department of Obstetrics and
Gynecology, Robert H. Lurie Comprehensive Cancer Center, Northwestern
University Feinberg School of Medicine, Chicago, USA. 2Division of
Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, USA.
3Department of Pathology, Roswell Park Cancer Institute, Buffalo, USA.
4Gynecologic Oncology Program, Cadence Physician Group, Warrenville, USA.
5Department of Preventive Medicine, Northwestern University Feinberg
School of Medicine, Chicago, USA. 6Department of Pathology, Robert H. Lurie
Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern
University, 251 East Huron Street, Feinberg 7-334, Chicago, IL 60611, USA.
7Division of Reproductive Science in Medicine, Department of Obstetrics and
Gynecology, Robert H. Lurie Comprehensive Cancer Center, Northwestern
University Feinberg School of Medicine, 303 E. Superior Street, 4-117,
Chicago, IL 60611, USA.
Received: 3 August 2016 Accepted: 17 October 2016
References
1. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet.
2014;384(9951):1376–88.
2. Howlader NNA, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M,
Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA.
SEER Cancer Statistics Review, 1975–2013. In: National Cancer Institute. 2016.
3. Nicosia SV, Bai W, Cheng JQ, Coppola D, Kruk PA. Oncogenic pathways
implicated in ovarian epithelial cancer. Hematol Oncol Clin North Am.
2003;17(4):927–43.
4. Singh VK, Jia Z. Targeting synuclein-gamma to counteract drug resistance in
cancer. Expert Opin Ther Targets. 2008;12(1):59–68.
5. George JM. The synucleins. Genome Biol. 2002;3(1):REVIEWS3002.
6. Lavedan C. The synuclein family. Genome Res. 1998;8(9):871–80.
7. Iwai A. Properties of NACP/alpha-synuclein and its role in Alzheimer’s
disease. Biochim Biophys Acta. 2000;1502(1):95–109.
8. von Bohlen Und Halbach O. Synucleins and their relationship to Parkinson’s
disease. Cell Tissue Res. 2004;318(1):163–74.
9. Ji H, Liu YE, Jia T, Wang M, Liu J, Xiao G, Joseph BK, Rosen C, Shi YE.
Identification of a breast cancer-specific gene, BCSG1, by direct differential
cDNA sequencing. Cancer Res. 1997;57(4):759–64.
10. Liu H, Liu W, Wu Y, Zhou Y, Xue R, Luo C, Wang L, Zhao W, Jiang JD, Liu J. Loss
of epigenetic control of synuclein-gamma gene as a molecular indicator of
metastasis in a wide range of human cancers. Cancer Res. 2005;65(17):7635–43.
11. Singh MN, Stringfellow HF, Taylor SE, Ashton KM, Ahmad M, Abdo KR, El-
Agnaf OM, Martin-Hirsch PL, Martin FL. Elevated expression of CYP1A1 and
gamma-SYNUCLEIN in human ectopic (ovarian) endometriosis compared
with eutopic endometrium. Mol Hum Reprod. 2008;14(11):655–63.
12. Jia T, Liu YE, Liu J, Shi YE. Stimulation of breast cancer invasion and
metastasis by synuclein gamma. Cancer Res. 1999;59(3):742–7.
13. Ahmad M, Attoub S, Singh MN, Martin FL, El-Agnaf OM. Gamma-synuclein
and the progression of cancer. FASEB J. 2007;21(13):3419–30.
14. Bruening W, Giasson BI, Klein-Szanto AJ, Lee VM, Trojanowski JQ, Godwin AK.
Synucleins are expressed in the majority of breast and ovarian carcinomas and
in preneoplastic lesions of the ovary. Cancer. 2000;88(9):2154–63.
15. Czekierdowski A, Czekierdowska S, Danilos J, Czuba B, Sodowski K,
Sodowska H, Szymanski M, Kotarski J. Microvessel density and CpG island
methylation of the THBS2 gene in malignant ovarian tumors. J Physiol
Pharmacol. 2008;59 Suppl 4:53–65.
16. Gupta A, Godwin AK, Vanderveer L, Lu A, Liu J. Hypomethylation of the
synuclein gamma gene CpG island promotes its aberrant expression in
breast carcinoma and ovarian carcinoma. Cancer Res. 2003;63(3):664–73.
17. Cheung KT, Taylor SE, Patel II, Bentley AJ, Stringfellow HF, Fullwood NJ,
Martin-Hirsch PL, Martin FL. Expression of ERalpha, its ERalphaDelta3 Splice
Variant and gamma-SYNUCLEIN in Ovarian Cancer: A Pilot Study. Br J Med
Med Res. 2011;1(4):430–44.
18. Fekete T, Raso E, Pete I, Tegze B, Liko I, Munkacsy G, Sipos N, Rigo Jr J,
Gyorffy B. Meta-analysis of gene expression profiles associated with
histological classification and survival in 829 ovarian cancer samples. Int J
Cancer. 2012;131(1):95–105.
19. Mhawech-Fauceglia P, Wang D, Syriac S, Godoy H, Dupont N, Liu S, Odunsi K.
Synuclein-gamma (SNCG) protein expression is associated with poor outcome
in endometrial adenocarcinoma. Gynecol Oncol. 2012;124(1):148–52.
20. Iwaki H, Kageyama S, Isono T, Wakabayashi Y, Okada Y, Yoshimura K, Terai A, Arai
Y, Iwamura H, Kawakita M, et al. Diagnostic potential in bladder cancer of a panel
of tumor markers (calreticulin, gamma -synuclein, and catechol-o-
methyltransferase) identified by proteomic analysis. Cancer Sci. 2004;95(12):955–61.
21. Li Z, Sclabas GM, Peng B, Hess KR, Abbruzzese JL, Evans DB, Chiao PJ.
Overexpression of synuclein-gamma in pancreatic adenocarcinoma. Cancer.
2004;101(1):58–65.
22. Liu C, Guo J, Qu L, Bing D, Meng L, Wu J, Shou C. Applications of novel
monoclonal antibodies specific for synuclein-gamma in evaluating its levels
in sera and cancer tissues from colorectal cancer patients. Cancer Lett. 2008;
269(1):148–58.
23. Liu C, Qu L, Lian S, Tian Z, Zhao C, Meng L, Shou C. Unconventional
secretion of synuclein-gamma promotes tumor cell invasion. FEBS J.
2014;281(22):5159–71.
24. Wu K, Weng Z, Tao Q, Lin G, Wu X, Qian H, Zhang Y, Ding X, Jiang Y, Shi YE.
Stage-specific expression of breast cancer-specific gene gamma-synuclein.
Cancer Epidemiol Biomarkers Prev. 2003;12(9):920–5.
25. Ye Q, Wang TF, Peng YF, Xie J, Feng B, Qiu MY, Li LH, Lu AG, Liu BY, Zheng
MH. Expression of alpha-, beta- and gamma-synuclein in colorectal cancer,
and potential clinical significance in progression of the disease. Oncol Rep.
2010;23(2):429–36.
26. Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian
carcinoma. Nature. 2011;474(7353):609–15.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Strohl et al. Journal of Ovarian Research  (2016) 9:75 Page 8 of 8
